| Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma (NCT01549886) | Spectrum Pharmaceuticals, Inc | 2011-11-01 |
| Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. (NCT01878890) | Institut Bergonié | 2011-09-05 |
| Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study (NCT01763398) | Yonsei University | 2011-09-01 |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (NCT01342289) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2011-08-01 |
| A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (NCT01332968) | Hoffmann-La Roche | 2011-07-06 |
| FLT PET: A Pilot Study in Lymphoma Patients (NCT04028804) | The Hospital for Sick Children | 2011-07-01 |
| EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (NCT01192464) | Baylor College of Medicine | 2011-05-10 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps (NCT01350258) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-04-01 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation (NCT01339572) | University of Florida | 2011-04-01 |
| Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases (NCT01336712) | Northside Hospital, Inc. | 2011-04-01 |
| A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (NCT01296555) | Genentech, Inc. | 2011-03-16 |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies (NCT01321346) | Therapeutic Advances in Childhood Leukemia Consortium | 2011-03-01 |
| Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma (NCT01180049) | Pfizer | 2011-03-01 |
| A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma (NCT01200758) | Hoffmann-La Roche | 2011-02-15 |
| A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (NCT01929265) | Fondazione Italiana Linfomi - ETS | 2011-01-01 |
| Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma (NCT01316523) | University of California, Davis | 2010-12-01 |
| PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study (NCT01269593) | Memorial Sloan Kettering Cancer Center | 2010-12-01 |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies (NCT01221857) | Gamida Cell ltd | 2010-11-01 |
| Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation (NCT01203020) | West Virginia University | 2010-10-12 |
| Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy (NCT01200589) | Novartis Pharmaceuticals | 2010-10-11 |
| SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) (NCT01402687) | Dana-Farber Cancer Institute | 2010-10-01 |
| Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms (NCT01164475) | Genzyme, a Sanofi Company | 2010-10-01 |
| Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release (NCT01205503) | Mara Chambers | 2010-09-01 |
| Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL (NCT01187810) | South Plains Oncology Consortium | 2010-08-01 |
| High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma (NCT01182415) | Massachusetts General Hospital | 2010-06-01 |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer (NCT01149668) | Pharmacyclics LLC. | 2010-06-01 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Mozobil for Autologous Stem Cell Mobilization (NCT01164345) | Sheba Medical Center | 2010-06-01 |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation (NCT01068301) | St. Jude Children's Research Hospital | 2010-05-01 |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL (NCT01101581) | Gilead Sciences | 2010-05-01 |
| A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) (NCT01059630) | Genentech, Inc. | 2010-04-30 |
| Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT01118845) | SymBio Pharmaceuticals | 2010-04-01 |
| A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (NCT01021423) | Celgene | 2010-04-01 |
| Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT01060384) | University of Nebraska | 2010-03-29 |
| Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) (NCT01090973) | H. Lee Moffitt Cancer Center and Research Institute | 2010-03-01 |
| Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) (NCT01073163) | Cephalon | 2010-02-01 |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation (NCT00984165) | National Cancer Institute (NCI) | 2010-01-19 |
| BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL) (NCT01063439) | Inje University | 2010-01-01 |
| Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma (NCT01032148) | Roswell Park Cancer Institute | 2009-12-01 |
| A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment (NCT01007292) | Astellas Pharma Inc | 2009-11-01 |
| Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL) (NCT03792815) | Soonchunhyang University Hospital | 2009-10-01 |
| Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma (NCT00969462) | Meir Medical Center | 2009-09-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers (NCT00788684) | AbbVie | 2009-07-21 |
| Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT00944905) | Bristol-Myers Squibb | 2009-07-01 |
| R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial (NCT01133158) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2009-07-01 |
| Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients (NCT00931229) | National Health Research Institutes, Taiwan | 2009-06-01 |
| Study of Repeat Intranodal Injections of Ad-ISF35 (NCT00942409) | Januario Castro, M.D. | 2009-06-01 |
| Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era (NCT00902434) | Oncology Specialists, S.C. | 2009-05-01 |
| Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study (NCT00877006) | Teva Branded Pharmaceutical Products R&D, Inc. | 2009-04-30 |
| Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B (NCT00926757) | Taipei Veterans General Hospital, Taiwan | 2009-04-01 |
| Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (NCT00840853) | Baylor College of Medicine | 2009-04-01 |
| Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas (NCT00877214) | Jurgen Barth | 2009-04-01 |
| Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT (NCT01144754) | Stanford University | 2009-02-01 |
| A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma (NCT00825149) | Hoffmann-La Roche | 2009-02-01 |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial (NCT02872987) | Goethe University | 2009-02-01 |
| Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) (NCT00864942) | Georgetown University | 2009-02-01 |
| R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (NCT00809341) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2009-01-01 |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (NCT00710892) | Baylor College of Medicine | 2008-12-01 |
| A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma (NCT00794638) | SymBio Pharmaceuticals | 2008-11-01 |
| Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant (NCT00909948) | Massachusetts General Hospital | 2008-11-01 |
| Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma (NCT00775957) | University of Oklahoma | 2008-10-01 |
| CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma (NCT00659425) | MedImmune LLC | 2008-09-01 |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (NCT00709592) | Virginia Commonwealth University | 2008-07-21 |
| Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma (NCT00712582) | Memorial Sloan Kettering Cancer Center | 2008-07-01 |
| A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) (NCT00719472) | Genentech, Inc. | 2008-07-01 |
| Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies (NCT00714259) | University of Alabama at Birmingham | 2008-07-01 |
| Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas (NCT00685997) | UMC Utrecht | 2008-06-01 |
| R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma (NCT00788606) | Royal Marsden NHS Foundation Trust | 2008-05-01 |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (NCT00670592) | Novartis Pharmaceuticals | 2008-03-01 |
| A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) (NCT00517049) | Genentech, Inc. | 2008-03-01 |
| Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT (NCT00648037) | Memorial Sloan Kettering Cancer Center | 2008-03-01 |
| A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00622258) | Novartis Pharmaceuticals | 2008-03-01 |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat (NCT00791011) | Amgen | 2008-02-01 |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant (NCT00597714) | David Rizzieri, MD | 2008-02-01 |
| GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma (NCT00576758) | Hoffmann-La Roche | 2008-01-01 |
| Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom (NCT00646750) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2008-01-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma (NCT00556699) | Genentech, Inc. | 2007-12-01 |
| Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma (NCT00612183) | SymBio Pharmaceuticals | 2007-12-01 |
| Investigation of the Cylex® ImmuKnow® Assay (NCT00569842) | Indiana University | 2007-11-01 |
| Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). (NCT00665314) | Genzyme, a Sanofi Company | 2007-11-01 |
| Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma (NCT00547534) | University of Rochester | 2007-10-01 |
| Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar (NCT00475332) | University of Florida | 2007-09-01 |
| Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma (NCT00533728) | Biotec Pharmacon ASA | 2007-09-01 |
| An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) (NCT00608907) | Millennium Pharmaceuticals, Inc. | 2007-09-01 |
| Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL (NCT00577161) | CTI BioPharma | 2007-09-01 |
| Positron Emission Tomography(PET) in Lymphoma Assessment (NCT00887718) | University Health Network, Toronto | 2007-08-01 |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease (NCT00515892) | Cambridge Antibody Technology | 2007-08-01 |
| Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant (NCT00510315) | Memorial Sloan Kettering Cancer Center | 2007-07-01 |
| A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) (NCT00499239) | Gilead Sciences | 2007-07-01 |
| Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials (NCT00487513) | Dana-Farber Cancer Institute | 2007-06-01 |
| Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies (NCT00504972) | Weill Medical College of Cornell University | 2007-06-01 |
| Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma (NCT00510471) | Genitope Corporation | 2007-05-01 |
| A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NCT00452127) | Genentech, Inc. | 2007-05-01 |
| Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (NCT01300793) | University of California, San Francisco | 2007-05-01 |
| Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL (NCT00504751) | Weill Medical College of Cornell University | 2007-05-01 |
| Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma (NCT00463463) | Soroka University Medical Center | 2007-04-01 |
| Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy (NCT00777114) | Weill Medical College of Cornell University | 2007-04-01 |